Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Somerset's Eldepryl for Parkinson's will be copromoted by Cocensys.

  • News

Executive Summary

SOMERSET's ELDEPRYL WILL BE COPROMOTED BY CONCENSYS and its 70-person CNS field force in place of Sandoz after the end of the first quarter. Somerset Pharmaceuticals, the joint venture of Mylan Labs and Watson Pharmaceuticals, has signed on Cocensys to copromote selegiline for the treatment of Parkinson's disease in the U.S. Sandoz has been marketing the drug since Oct. 1, 1990. The companies agreed in 1995 to terminate that deal after March 31.

Table

View full table

Tags:
Latest Headlines

EU Launches Critical Medicines Alliance But Prospect Of Act On Manufacturing Still Uncertain

‘Shocking’ MHRA Performance & Poor Data Transparency Blamed For UK’s Clinical Trial Crisis

Updated COVID-19 Vaccines Should Target New JN.1 Variant, Says EMA

EMA Pilots Partnering With Companies To Gain Efficiencies In Preparing Drug Assessment Reports

See All
UsernamePublicRestriction

Register

PS027468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By